Distinct changes in brain and peripheral oxygen levels induced by synthetic opioids of the nitazene family
Nitazenes are a category of synthetic opioids, some of which have high analgesic potential but also high toxicity, which has historically prevented their development as therapeutic drugs. Like fentanyl, nitazenes induce respiratory depression, a primary factor in their toxicity. Recently, a nitazene derivative called N-desethyl-fluornitrazene (DFNZ) was shown to have high analgesic properties with weak hypoxic effects. To better characterize the hypoxic effects of DFNZ relative to its parent, fluornitrazene (FNZ) and the prototypical nitazene etonitazene, we used amperometric oxygen sensors in freely moving rats to examine oxygen dynamics in the nucleus accumbens (NAc) and the subcutaneous space, using fentanyl as a comparison. All drugs induced similar patterns of subcutaneous hypoxia, with rapid dose-dependent oxygen decreases. In the NAc, all opioids, except DFNZ, at low iv doses (1-5 g/kg) induced moderate but significant brain oxygen increases. At higher doses (>10 g/kg), oxygen levels for all opioids, except DFNZ, showed a biphasic response; robust hypoxia followed by a weaker rebound-like hyperoxia. Etonitazene at 30 g/kg had the largest and most prolonged brain hypoxia compared to the other drugs, without the rebound-like hyperoxia. These findings indicate that etonitazene and FNZ mimic the effects of fentanyl, inducing dose-dependent brain and peripheral hypoxia. In contrast, DFNZ induces very weak hypoxia seen minimally at very high iv doses (300-1000 g/kg). Our findings substantiate the low hypoxic potency of DFNZ and indicate that not all nitazenes are characterized by high potential for toxicity. As such, the development of nitazenes as analgesics should not be categorically dismissed.